- Biosimilars | FDA
FDA approved biosimilars are safe, effective treatment options Biosimilars may provide more treatment options, increase access to lifesaving medications and potentially lower health care costs
- Biosimilar - Wikipedia
Unlike with generic drugs of the more common small-molecule type, biosimilar drugs generally exhibit high molecular complexity and may be quite sensitive to changes in manufacturing processes
- Biosimilars vs Biologics: What are they and how do they compare?
Biosimilars are meant to be more affordable than the reference product They are expected to help the U S healthcare system and consumers save money, but biosimilar products are still very expensive and unaffordable for most patients without prescription insurance
- Biosimilars: expanding access to essential biologic therapies
Biologic medicines have transformed treatment for numerous chronic and life-threatening conditions such as cancer, auto-immune diseases, and diabetes These therapies can offer significant benefits in efficacy, safety, and convenience, compared to conventional medicines
- Biosimilars 101 - SmithRx
Biosimilars are highly similar versions of biologic drugs and are designed to work just like the reference products in terms of safety, strength, dosage, and clinical outcome - but at a significantly lower cost
- What Are Biosimilars? Definition and Examples - GoodRx
Biologics are complex medications that come from living or natural sources instead of chemicals They’re often used to treat autoimmune disorders, cancer, diabetes, and more A biosimilar is a highly similar version of a particular biologic
- What are Biologic Medicines and Biosimilars? - Abbott
Over the past few decades, biosimilars have emerged They are medicines developed to be highly similar to an already-approved biologic Biosimilars may be available at a lower price than the originator biologics, and therefore have the potential to make biologics more affordable and accessible to more people around the world
- An Overview of Biosimilars—Development, Quality, Regulatory Issues, and . . .
As the patent and exclusivity period for biological medicines draws to a close, there is a possibility for the development and authorization of biosimilars These products boast comparable levels of safety, quality, and effectiveness to their precursor reference products
|